Anthelmintic Drugs Market Report 2026

The anthelmintic drugs market size has grown strongly in recent years. It will grow from $3.34 billion in 2025 to $3.53 billion in 2026 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to high prevalence of parasitic infections, limited access to advanced anthelmintic drugs, reliance on traditional drug classes, growing awareness of helminth infections, expanding hospital and clinic infrastructure.

The anthelmintic drugs market size is expected to see strong growth in the next few years. It will grow to $4.32 billion in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to development of novel anthelmintic compounds, increasing adoption of combination therapies, rising veterinary and livestock applications, expansion of online and retail pharmacy channels, government initiatives for parasite control programs. Major trends in the forecast period include rising prevalence of helminth infections in humans and animals, growing adoption of oral anthelmintics and injectable formulations, increasing demand for veterinary anthelmintics in livestock management, expansion of retail and online pharmacy channels for anthelmintic drugs, focus on combination therapies and broad-spectrum anthelmintics.

The widespread prevalence of parasitic infections is expected to drive the growth of the anthelmintic drugs market in the coming years. Parasitic infections are illnesses caused by organisms that live on or within a host, including parasites such as protozoa, worms, or ectoparasites. The occurrence of parasitic infections is driven by factors such as poor sanitation, contaminated food and water, close contact with infected humans or animals, insufficient hygiene practices, and limited access to clean resources. Anthelmintic drugs are used to treat infections caused by parasitic worms by effectively targeting and removing these organisms from the host’s body. These drugs act by interfering with the parasites’ biological processes, ultimately resulting in their expulsion or death. For example, in September 2025, according to data published by the Centers for Disease Control and Prevention, a US-based national public health agency, as of September 16, 2025, the CDC had received reports of 990 cases of cyclosporiasis acquired within the United States. Therefore, the high prevalence of parasitic infections is contributing to the growth of the anthelmintic drugs market.

Leading companies operating in the anthelmintic drugs market are emphasizing the development of innovative approaches, such as targeted and evidence-based deworming programs, to enhance parasite control, limit drug resistance, and encourage the sustainable use of anthelmintics compared with conventional blanket deworming strategies that often depend on frequent, non-targeted treatments. Targeted deworming programs utilize diagnostic testing, parasite burden evaluation, and planned dosing regimens to maximize treatment effectiveness while reducing environmental impact and resistance risks. For instance, in April 2025, Zoetis Inc., a US-based animal health company, introduced the “Buy Less Dewormer” campaign for equine populations, promoting evidence-based parasite management. This initiative integrates educational resources with guidance on fecal egg count monitoring and strategic selection of anthelmintics, encouraging veterinarians and horse owners to administer treatments only when necessary based on parasite load and risk assessment. Key features include comprehensive educational materials, risk-based treatment guidance, and support for sustainable anthelmintic stewardship, with applications in equine herd health management, resistance prevention, and optimized deworming schedules. The benefits include reduced overuse of anthelmintic drugs, improved parasite control outcomes, lower costs for owners, and preservation of long-term drug effectiveness.

In July 2023, Bayer AG, a Germany-based pharmaceutical and biotechnology company, entered into a partnership with the Swiss Tropical and Public Health Institute (Swiss TPH) to develop anthelmintic drug candidates for the treatment of parasitic infections. This collaboration is focused on assessing the safety and effectiveness of emodepside, a compound originally developed for veterinary applications, for use in treating soil-transmitted helminths in humans. The partnership aims to introduce a new therapeutic option and support global health initiatives by addressing a significant public health issue in developing regions. The Swiss Tropical and Public Health Institute (Swiss TPH) is a Switzerland-based research organization specializing in global health and tropical disease research.

Major companies operating in the anthelmintic drugs market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Limited, Zoetis Inc., Hetero Labs Limited, Sun Pharmaceutical Industries Ltd., Galderma S.A., Cipla Inc., Ferring Pharmaceuticals Inc., Amneal Pharmaceuticals Inc., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Mankind Pharma Ltd., Reese Pharmaceutical Company.

North America was the largest region in the anthelmintic drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthelmintic drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anthelmintic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the anthelmintic drugs market by increasing the cost of imported active pharmaceutical ingredients and finished drugs, which has affected both human and veterinary segments. Oral and injectable formulations imported from Asia-Pacific regions such as India and China are most affected, leading to higher treatment costs and supply chain delays. On the positive side, tariffs have encouraged domestic production, local manufacturing of generic anthelmintics, and innovation in combination and broad-spectrum drug formulations.

The anthelmintic drugs market research report is one of a series of new reports that provides anthelmintic drugs market statistics, including anthelmintic drugs industry global market size, regional shares, competitors with a anthelmintic drugs market share, detailed anthelmintic drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anthelmintic drugs industry. This anthelmintic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anthelmintic drugs are medications designed to treat infections caused by parasitic worms, known as helminths. These drugs function by either destroying the worms or interfering with their ability to reproduce and survive. They are commonly used to manage infections such as roundworm, tapeworm, and hookworm infestations.

The primary classes of anthelmintic drugs include benzimidazoles, macrocyclic lactones, pyrazinoisoquinolones, tetrahydropyrimidines, and others. Benzimidazoles are a group of organic compounds featuring a benzene ring fused to an imidazole ring. They are widely used in multiple applications, including as pharmaceutical agents for the treatment of parasitic infections and as important components in certain synthetic materials. These drugs are administered through oral and injectable routes to treat a range of infections, including nematode, cestode, trematode, and mixed infections. They are distributed through channels such as hospitals and clinics, retail pharmacies, online pharmacies, veterinary clinics, and supply stores, and are used in both human and veterinary anthelmintic applications.

The anthelmintic drugs market consists of sales of albendazole, mebendazole, praziquantel, levamisole, piperazine, and ivermectin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.